Physician support for a population-based pharmaceutical approach to cardiovascular prevention: Not there yet

Preventive Medicine

Volumn 52, Issue 1, 2011, Pages 18-19

  Huy, Christina ^a   Litaker, David ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG FORMULATION; DRUG UTILIZATION; HIGH RISK POPULATION; HUMAN; MEDICAL EDUCATION; NOTE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PILL; POLYPILL; POPULATION RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION;

ANTIHYPERTENSIVE AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHYSICIAN'S PRACTICE PATTERNS; PREVENTIVE MEDICINE; PRIMARY PREVENTION;

EID: 78650526995     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ypmed.2010.11.017     Document Type: Note

References (11)

1. Beaglehole R., Magnus P. The search for new risk factors for coronary heart disease: occupational therapy for epidemiologists?. Int. J. Epidemiol. 2002, 31:1117-1122.
2. Chiriboga D.E., Ockene J.K., Ockene I.S. Barriers to preventive interventions for coronary heart disease. Cardiol. Clin. 2003, 21:459-470.
3. Emberson J., Whincup P., Morris R., Walker M., Ebrahim S. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur. Heart J. 2004, 25:484-491.
4. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J.L. Global Burden of Disease and Risk Factors 2006, Oxford University Press, New York.
5. Mensah G.A., Brown D.W. An overview of cardiovascular disease burden in the United States. Health Aff. 2007, 26:38-48.
6. Pearson T.A., Blair S.N., Daniels S.R., Eckel R.H., Fair J.M., Fortmann S.P., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke. 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002, 106:388-391.
7. Rose G., Khaw K.T., Marmot M. Rose's Strategy of Preventive Mmedicine 2008, Oxford University Press, New York.
8. Smith S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease. 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363-2372.
9. Viera A.J., Sheridan S.L., Edwards T., Soliman E.Z., Harris R., Furberg C.D. Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev. Med. 2011, 52:10-15.
10. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. Br. Med. J. 2003, 326:1419.
11. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.